Psilocybin Therapy Shows 75% PTSD Remission Rate in Veteran Trial

A clinical trial evaluating psilocybin-assisted therapy in military veterans with treatment-resistant post-traumatic stress disorder has reported a 75% remission rate, according to researchers who conducted the study.

Structured therapy alongside the compound

The 11-week pilot trial combined 14 to 16 hours of preparation and integration therapy sessions with administration of psilocybin, researchers said, describing the structured approach as central to the results.

Participants were veterans who had not responded to conventional PTSD treatments, according to the study's authors, making the remission rate particularly notable for a difficult-to-treat population.

• The trial enrolled veterans with treatment-resistant PTSD
• 75% of participants met criteria for remission by the trial's end
• Researchers reported no major safety concerns during the pilot

Part of a growing field

The study adds to a growing body of research into psychedelic-assisted therapies for mental health conditions, though experts cautioned that larger, controlled trials are still needed before wider clinical use.

Researchers said the next phase would involve a larger, randomised trial to confirm the findings and better understand long-term outcomes.

Veterans' health advocates said the results, while preliminary, offer hope for a population that has often struggled to find effective treatment for chronic PTSD.